Description of Invention: The subject invention describes a novel and highly potent inhibitor of HIV-1 integrase (IN) that has high efficacy against the major forms of Raltegravir-resistant mutant forms of IN. Thus, this IN inhibitor can be developed as a therapeutic for patients who have developed resistance to current IN inhibitors, such as Raltegravir and Elvitegravir.
High efficacy against the major forms of Raltegravir-resistant mutant forms of IN in in vitro and whole cell assays.
An HIV therapeutic for patients resistant to current IN inhibitors.
For Licensing Information Please Contact: Sally Hu Ph.D., M.B.A. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 21, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-5606 Fax: 301-402-0220